Total Funding
76
54
Total FundingPost-IPO Equity raised
Growth Score
-18 pts
Heat Score
-21 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
17509
Apimeds Pharmaceuticals is a company that develops therapeutic application solutions for honeybee venom used for inflammatory conditions.
- Brian Peters: Senior Vice President of the ai² Division
- Erik Emerson: Chief Executive Officer
Lōkahi Therapeutics
About the Company
Apimeds Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing Apitox, an intradermally administered, purified bee venom-based biologic licensed from Apimeds Korea. Apitox is being evaluated as a potential treatment for knee osteoarthritis in patients unresponsive to conventional therapies. Apimeds Pharmaceuticals
is also exploring Apitox's application in managing symptoms of multiple sclerosis.
